Effective Date:

Monday, March 05, 2012

New Tests and Test Updates

In our continuing effort to provide you with the highest quality toxicology laboratory services available, we have compiled important changes regarding a number of tests we perform. Listed below are the types of changes that may be included in this notification, effective Monday, March 05, 2012

New Tests - Tests recently added to the NMS Labs test menu. *New Tests are effective immediately.*

Test Changes - Tests that have had changes to the method/ CPT code, units of measurement, scope of analysis, reference comments, or specimen requirements.

Discontinued Tests - Tests being discontinued with alternate testing suggestions.

Please use this information to update your computer systems/records. These changes are important to ensure standardization of our mutual laboratory databases.

If you have any questions about the information contained in this notification, please call our Client Support Department at (866) 522-2206. Thank you for your continued support of NMS Labs and your assistance in implementing these changes.

The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. NMS Labs does not assume responsibility for billing errors due to reliance on the CPT Codes listed in this document.

NMS LABS
3701 Welsh Road
Willow Grove, PA 19090
www.NMSLabs.com

Effective Date:

Monday, March 05, 2012

New Tests and Test Updates

Test Code	Test Name	New Test	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
8890OF	Amphetamines Panel (Qualitative), Oral Fluids	•								
0478FL	Astemizole and Metabolite, Fluid									•
0478SP	Astemizole and Metabolite, Serum/Plasma									•
0478TI	Astemizole and Metabolite, Tissue									•
8891OF	Benzodiazepines Panel (Qualitative), Oral Fluids	•								
1140P	Chloroquine, Plasma	•								
1140SP	Chloroquine, Serum/Plasma									•
8893OF	Cocaine and Metabolites (Qualitative), Oral Fluids	•								
8892OF	Delta-9 THC (Qualitative), Oral Fluids	•								
2526B	Leflunomide as Metabolite, Blood				•					
2543B	Lurasidone, Blood	•								
2543SP	Lurasidone, Serum/Plasma	•								
8894OF	Methadone and Metabolite (Qualitative), Oral Fluids	•								
8602B	Methamphetamine and Metabolite, Blood									•
8602FL	Methamphetamine and Metabolite, Fluid									•
8602SP	Methamphetamine and Metabolite, Serum/Plasma									•
8602TI	Methamphetamine and Metabolite, Tissue									•
2810U	Methamphetamine and Metabolite, Urine	•								
8602U	Methamphetamine and Metabolite, Urine									•
8895OF	Opiates (Qualitative), Oral Fluids	•								
8896OF	Phencyclidine and Dextromethorphan (Qualitative), Oral Fluids	•								
4030B	Pyridine, Blood							•		
4030SP	Pyridine, Serum/Plasma							•		
4030U	Pyridine, Urine							•		
4790B	Vilazodone, Blood	•								
4790SP	Vilazodone, Serum/Plasma	•								

New Tests and Test Updates

New Tests

8890OF Amphetamines Panel (Qualitative), Oral Fluids **Effective Immediately**

Scope of Analysis:	Amphetamine [LC-MS/MS], MDA [LC-MS/MS], MDMA [LC-MS/MS], Methamphetamine [LC-MS/MS]
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Identification by LC-MS/MS
Category:	Stimulant, Stimulant, Anorexogenic
Specimen Requirements:	1 mL Oral Fluid
Minimum Volume:	0.7 mL
Special Handling:	Use either an OraSure Intercept® or Immunalysis QuantisalTM collection device and follow the manufacturer's directions. It is recommended that samples be submitted in the original collection device. However, pour-off containers will be accepted. Samples are stable up to 3 days at room temperature and should be refrigerated thereafter. DO NOT FREEZE the OraSure Intercept® or Immunalysis QuantisalTM collection devices.
Specimen Container:	Oral Fluid collection device
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Stability:	Room Temperature: Undetermined Refrigerated: 21 day(s) Frozen (-20 °C): Undetermined

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Thursday 2 days (after set-up)

CPT Code: 83788

Compound Name / Alias	Units	RL	Reference Comment
Amphetamine	ng/mL	10	Amphetamine (Adderall, Dexedrine) is a Schedule II phenethylamine CNS-stimulant. It is used therapeutically in the treatment of narcolepsy and obesity and also in the treatment of attention deficit/hyperactivity disorder. Amphetamine has a high potential for abuse and dependence.
Methamphetamine	ng/mL	10	d-Methamphetamine (Desoxyn) is a DEA schedule II stimulant drug, subject to abuse and dependence. Chemically, there are two forms (isomers) of methamphetamine: l- and d-methamphetamine. This test does not distinguish between these two isomers.
MDA Adam; Methylenedioxyamphetamine	ng/mL	10	3,4-Methylenedioxyamphetamine (MDA) is an amphetamine derivative and a chemical analogue and metabolite of 3,4-methylenedioxymethamphetamine (MDMA). This compound is abused for its central nervous system stimulant and hallucinogenic properties.
MDMA Ecstasy; Methylenedioxymethamphetamine	ng/mL	10	3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy) is a DEA Schedule I controlled substance and is a synthetic sympathomimetic compound with mixed stimulant, psychotropic, and hallucinogenic activities. This compound Is abused for its central nervous system stimulant and hallucinogenic properties.

New Tests and Test Updates

New Tests

8891OF Benzodiazepines Panel (Qualitative), Oral Fluids **Effective Immediately**

Scope of Analysis:	Alprazolam [LC-MS/MS], Chlordiazepoxide [LC-MS/MS], Clonazepam [LC-MS/MS], Diazepam [LC-MS/MS], Lorazepam [LC-MS/MS], Midazolam [LC-MS/MS], Nordiazepam [LC-MS/MS], Oxazepam [LC-MS/MS], Temazepam [LC-MS/MS]
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Identification by LC-MS/MS
Category:	Anxiolytic, Sedative, Anticonvulsant
Specimen Requirements:	1 mL Oral Fluid
Minimum Volume:	0.7 mL
Special Handling:	Use either an OraSure Intercept® or Immunalysis QuantisalTM collection device and follow the manufacturer's directions. It is recommended that samples be submitted in the original collection device. However, pour-off containers will be accepted. Samples are stable up to 3 days at room temperature and should be refrigerated thereafter. DO NOT FREEZE the OraSure Intercept® or Immunalysis QuantisalTM collection devices.
Specimen Container:	Oral Fluid collection device
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Stability:	Room Temperature: Undetermined Refrigerated: 21 day(s) Frozen (-20 °C): Undetermined

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT:	Thursday 2 days (after set-up)
CPT Code:	83788

Compound Name / Alias	Units	RL	Reference Comment
Diazepam Valium®	ng/mL	6.0	Diazepam (Valium) is a schedule IV benzodiazepine used primarily for its sedative, anxiolytic, anticonvulsant, or muscle relaxing effects, and is a CNS depressant.
Nordiazepam	ng/mL	6.0	Nordiazepam is a pharmacologically active metabolite of several benzodiazepine anxiolytic/sedative/hypnotic agents including diazepam.
Oxazepam Serax®	ng/mL	9.0	Oxazepam is a DEA schedule IV benzodiazepine with CNS depressant properties. It is frequently seen as the metabolite of diazepam and other benzodiazepines.
Temazepam Normison®; Restoril®	ng/mL	6.0	Temazepam (Restoril) is a DEA schedule IV benzodiazepine hypnotic agent used in the short-term relief of insomnia. It has CNS depressant properties. Temazepam is also a metabolite of diazepam (Valium).
Chlordiazepoxide Librium®	ng/mL	100	Chlordiazepoxide (Librium) is a benzodiazepine with CNS depressant properties used for the management of anxiety and for aid in alcohol withdrawal.
Lorazepam Ativan®	ng/mL	6.0	Lorazepam (Ativan) is a DEA Schedule IV benzodiazepine with CNS depressant properties, used in the treatment of anxiety and for short-term relief of anxiety associated with depressive symptoms.
Clonazepam Klonopin®	ng/mL	6.0	Clonazepam (Klonopin) is a DEA Schedule IV benzodiazepine-derivative anticonvulsant agent with CNS depressant properties. It is used in both the prophylaxis and treatment of various seizure disorders.
Alprazolam Xanax®	ng/mL	6.0	Alprazolam (Xanax) is a DEA Schedule IV second-generation benzodiazepine with CNS depressant properties. It is effective at low doses, and is used in the management of anxiety disorders.

New Tests and Test Updates

New Tests

Compound Name / Alias	Units	RL	Reference Comment
Midazolam Versed®	ng/mL	9.0	Midazolam (Versed) is a DEA schedule IV short acting benzodiazepine with strong central nervous system depressant/hypnotic properties.

1140P Chloroquine, Plasma — Effective Immediately

Scope of Analysis: Chloroquine [LC-MS/MS]
Method(s): High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose: Therapeutic Drug Monitoring
Category: Antimalarial
Specimen Requirements: 1 mL Plasma
Minimum Volume: 0.4 mL
Special Handling: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Plasma into a plastic screw capped vial using approved guidelines.
Specimen Container: Plastic container (preservative-free)
Transport Temperature: Refrigerated
Light Protection: Not Required
Rejection Criteria: Polymer gel separation tube (SST or PST).
Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Tuesday 3 days (after set-up)
CPT Code: 83789

Compound Name / Alias	Units	RL	Reference Comment
Chloroquine Aralen®; Reumachlor®	ng/mL	10	Eleven adults given an infused 300 mg dose developed peak plasma chloroquine concentrations averaging 840 ng/mL. Ten pediatric malaria patients given a 10 mg/kg initial dose with an additional 5 mg/kg every 12 hours had peak plasma concentrations of 250 +/- 30 ng/mL at approximately 2 hours.

8893OF Cocaine and Metabolites (Qualitative), Oral Fluids — Effective Immediately

Scope of Analysis: Benzoylecognine [LC-MS/MS], Cocaethylene [LC-MS/MS], Cocaine [LC-MS/MS]
Method(s): High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose: Identification by LC-MS/MS
Category: Stimulant
Specimen Requirements: 1 mL Oral Fluid
Minimum Volume: 0.7 mL
Special Handling: Use either an OraSure Intercept® or Immunalysis QuantisalTM collection device and follow the manufacturer's directions. It is recommended that samples be submitted in the original collection device. However, pour-off containers will be accepted. Samples are stable up to 3 days at room temperature and should be refrigerated thereafter. DO NOT FREEZE the OraSure Intercept® or Immunalysis QuantisalTM collection devices.
Specimen Container: Oral Fluid collection device

New Tests and Test Updates

New Tests

Transport Temperature: Refrigerated
Light Protection: Not Required
Rejection Criteria: None
Stability: Room Temperature: Undetermined
Refrigerated: 21 day(s)
Frozen (-20 °C): Undetermined

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Thursday 2 days (after set-up)
CPT Code: 83788

Compound Name / Alias	Units	RL	Reference Comment
Cocaine	ng/mL	10	Cocaine is a DEA Schedule II controlled central nervous stimulant drug. Cocaine has a high potential for abuse and dependence.
Benzoylecognine Cocaine Degradation Product	ng/mL	6.0	Benzoylecgonine is an inactive metabolite and chemical breakdown product of cocaine. Cocaine is a DEA Schedule II controlled central nervous stimulant drug. Cocaine has a high potential for abuse and dependence.
Cocaethylene Cocaine/Ethanol By-Product	ng/mL	6.0	Cocaethylene is a transesterification artifact formed in vivo when cocaine and alcohol are taken together. It is an active metabolite of cocaine.

8892OF Delta-9 THC (Qualitative), Oral Fluids — Effective Immediately

Scope of Analysis: Delta-9 THC [GC/MS]
Method(s): Gas Chromatography/Mass Spectrometry (GC/MS)
Purpose: Identification by GC/MS
Category: Hallucinogen
Specimen Requirements: 1 mL Oral Fluid
Minimum Volume: 0.7 mL
Special Handling: Use either an OraSure Intercept® or Immunalysis QuantisalTM collection device and follow the manufacturer's directions. It is recommended that samples be submitted in the original collection device. However, pour-off containers will be accepted. Samples are stable up to 3 days at room temperature and should be refrigerated thereafter. DO NOT FREEZE the OraSure Intercept® or Immunalysis QuantisalTM collection devices.
Specimen Container: Oral Fluid collection device
Transport Temperature: Refrigerated
Light Protection: Not Required
Rejection Criteria: None
Stability: Room Temperature: Undetermined
Refrigerated: 21 day(s)
Frozen (-20 °C): Undetermined

Method: Gas Chromatography/Mass Spectrometry (GC/MS)

Set-Up Days / TAT: Thursday 2 days (after set-up)
CPT Code: 82541

Compound Name / Alias	Units	RL	Reference Comment
Delta-9 THC Active Ingredient of Marijuana; delta-9 tetrahydrocannabinol	ng/mL	2.0	Delta-9-THC is the active component in marijuana. Marijuana is a DEA Schedule I hallucinogen. THC may persist in the oral cavity for several hours following smoking of marijuana.

New Tests and Test Updates

New Tests

2543B Lurasidone, Blood — Effective Immediately

Scope of Analysis:	Lurasidone [LC-MS/MS]
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Therapeutic Drug Monitoring
Category:	Antipsychotic
Specimen Requirements:	1 mL Blood
Minimum Volume:	0.3 mL
Special Handling:	None
Specimen Container:	Gray top tube (Sodium Fluoride / Potassium Oxalate)
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Stability:	Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Monday-Sunday 7 days (after set-up)

CPT Code: 83789

Compound Name / Alias	Units	RL	Reference Comment
Lurasidone Latuda®	ng/mL	2.5	Following single dose administration of 40 mg and 80 mg, the mean Cmax values in serum were approximately 54 and 64 ng/mL, respectively. Following steady-state administration of 40 mg and 80 mg, the mean Cmax values in serum were approximately 48 and 79 ng/mL, respectively. Peak serum concentrations and absorption occur in approximately 1 to 3 hours. Steady-state concentrations are reached within 7 days of initiation of therapy. The elimination half-life is approximately 18 hours. The white blood cell (WBC) count should be monitored periodically, because agranulocytosis, leukopenia, and neutropenia have been reported during clinical trials. The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte.

2543SP Lurasidone, Serum/Plasma — Effective Immediately

Scope of Analysis:	Lurasidone [LC-MS/MS]
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Therapeutic Drug Monitoring
Category:	Antipsychotic
Specimen Requirements:	1 mL Serum or Plasma
Minimum Volume:	0.3 mL
Special Handling:	Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Specimen Container:	Plastic container (preservative-free)

New Tests and Test Updates

New Tests

Transport Temperature: Refrigerated
Light Protection: Not Required
Rejection Criteria: Polymer gel separation tube (SST or PST).
Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Monday-Sunday 7 days (after set-up)
CPT Code: 83789

Compound Name / Alias	Units	RL	Reference Comment
Lurasidone Latuda®	ng/mL	2.5	Following single dose administration of 40 mg and 80 mg, the mean Cmax values in serum were approximately 54 and 64 ng/mL, respectively. Following steady-state administration of 40 mg and 80 mg, the mean Cmax values in serum were approximately 48 and 79 ng/mL, respectively. Peak serum concentrations and absorption occur in approximately 1 to 3 hours. Steady-state concentrations are reached within 7 days of initiation of therapy. The elimination half-life is approximately 18 hours. The white blood cell (WBC) count should be monitored periodically, because agranulocytosis, leukopenia, and neutropenia have been reported during clinical trials.

8894OF Methadone and Metabolite (Qualitative), Oral Fluids **Effective Immediately**

Scope of Analysis: EDDP [LC-MS/MS], Methadone [LC-MS/MS]
Method(s): High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose: Identification by LC-MS/MS
Category: Narcotic Analgesic
Specimen Requirements: 1 mL Oral Fluid
Minimum Volume: 0.7 mL
Special Handling: Use either an OraSure Intercept® or Immunalysis QuantisalTM collection device and follow the manufacturer's directions. It is recommended that samples be submitted in the original collection device. However, pour-off containers will be accepted. Samples are stable up to 3 days at room temperature and should be refrigerated thereafter. DO NOT FREEZE the OraSure Intercept® or Immunalysis QuantisalTM collection devices.
Specimen Container: Oral Fluid collection device
Transport Temperature: Refrigerated
Light Protection: Not Required
Rejection Criteria: None
Stability: Room Temperature: Undetermined
Refrigerated: 21 day(s)
Frozen (-20 °C): Undetermined

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Thursday 2 days (after set-up)
CPT Code: 83788

Compound Name / Alias	Units	RL	Reference Comment
Methadone Dolophine®	ng/mL	10	Methadone (Dolophine) is a DEA Schedule II narcotic analgesic drug used in the treatment of narcotic (heroin) addiction, and for the treatment of pain.

New Tests and Test Updates

New Tests

Compound Name / Alias	Units	RL	Reference Comment
EDDP Methadone Metabolite	ng/mL	10	EDDP is a metabolite of the synthetic opioid drug methadone.

2810U Methamphetamine and Metabolite, Urine — Effective Immediately

Scope of Analysis:	Amphetamine [LC-MS/MS], Methamphetamine [LC-MS/MS]
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Therapeutic Drug Monitoring
Category:	Stimulant, Stimulant, Anorexogenic
Specimen Requirements:	1 mL Urine
Minimum Volume:	0.22 mL
Special Handling:	None
Specimen Container:	Plastic container (preservative-free)
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Stability:	Room Temperature: 16 day(s) Refrigerated: 16 day(s) Frozen (-20 °C): 16 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT:	Monday-Friday 2nd Shift 3 days (after set-up)
CPT Code:	82145

Compound Name / Alias	Units	RL	Reference Comment
Amphetamine Methamphetamine Metabolite	ng/mL	50	
Methamphetamine	ng/mL	50	During the first 24 hours after ingestion of 10 mg: 500 - 4000 ng/mL. This test reports Methamphetamine as the total of the undifferentiated d and l enantiomers. The ratio of these enantiomers is important in determining whether the source of Methamphetamine is from over the counter medications, prescribed medication or controlled substances. Call lab for further information on d to l enantiomer ratio determination.

8895OF Opiates (Qualitative), Oral Fluids — Effective Immediately

Scope of Analysis:	6-Monoacetylmorphine - Free [LC-MS/MS], Codeine - Free [LC-MS/MS], Dihydrocodeine - Free [LC-MS/MS], Hydrocodone - Free [LC-MS/MS], Hydromorphone - Free [LC-MS/MS], Morphine - Free [LC-MS/MS], Oxycodone - Free [LC-MS/MS], Oxymorphone - Free [LC-MS/MS]
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Identification by LC-MS/MS
Category:	Stimulant, Anorexogenic, Narcotic Analgesic
Specimen Requirements:	1 mL Oral Fluid
Minimum Volume:	0.7 mL
Special Handling:	Use either an OraSure Intercept® or Immunalysis QuantisalTM collection device and follow the manufacturer's directions. It is recommended that samples be submitted in the original collection device. However, pour-off containers will be accepted. Samples are stable up to 3 days at room temperature and should be refrigerated thereafter. DO NOT FREEZE the OraSure Intercept® or Immunalysis QuantisalTM collection devices.

New Tests and Test Updates

New Tests

Specimen Container: Oral Fluid collection device
Transport Temperature: Refrigerated
Light Protection: Not Required
Rejection Criteria: None
Stability: Room Temperature: Undetermined
Refrigerated: 21 day(s)
Frozen (-20 °C): Undetermined

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Thursday 2 days (after set-up)
CPT Code: 83788

Compound Name / Alias	Units	RL	Reference Comment
Codeine - Free	ng/mL	8.0	Codeine is a DEA Schedule III narcotic analgesic with central nervous system depressant activity.
Morphine - Free	ng/mL	8.0	Morphine is a DEA Schedule II narcotic analgesic used in the treatment of severe and chronic pain. Morphine is also a metabolite of heroin and codeine, and is subject to abuse and dependence.
Hydrocodone - Free Dicodid®	ng/mL	8.0	Hydrocodone (Vicodin, Lortab) is a schedule III opioid with narcotic analgesic, and antitussive properties.
6-Monoacetylmorphine - Free Heroin Metabolite	ng/mL	8.0	6-monoacetylmorphine (6-MAM) is the 6-monoacetylated form of morphine, which is pharmacologically active. When present it is indicative of heroin (diacetylmorphine) use.
Hydromorphone - Free Dilaudid®; Hydrocodone Metabolite	ng/mL	8.0	Hydromorphone (Dilaudid) is a schedule II opioid with narcotic analgesic properties. It is also a metabolite of hydrocodone and minor metabolite of morphine.
Oxycodone - Free OxyContin®; Roxicodone®	ng/mL	8.0	Oxycodone (Percodan, Oxycontin) is a DEA Schedule II controlled semi-synthetic opioid and narcotic analgesic. It is used in the treatment of moderate to severe pain and is subject to abuse and dependence.
Oxymorphone - Free Numorphan®; Opana®; Oxycodone Metabolite	ng/mL	8.0	Oxymorphone (Opana) is a DEA schedule II semisynthetic opioid analgesic. It is indicated for use in the relief of moderate to severe pain and as a preanesthetic medication. Oxymorphone is an active metabolite of oxycodone.
Dihydrocodeine - Free	ng/mL	8.0	Dihydrocodeine is a schedule II opioid analgesic. Preparations with small amounts may be schedule III or IV. It is available as a therapeutic agent for oral use and can be formed in vivo as a metabolite of hydrocodone.

8896OF Phencyclidine and Dextromethorphan (Qualitative), Oral Fluids **Effective Immediately**

Scope of Analysis: Dextromethorphan [LC-MS/MS], Phencyclidine [LC-MS/MS]
Method(s): High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose: Identification by LC-MS/MS
Category: Antitussive, Hallucinogen
Specimen Requirements: 1 mL Oral Fluid
Minimum Volume: 0.7 mL
Special Handling: Use either an OraSure Intercept® or Immunalysis QuantisalTM collection device and follow the manufacturer's directions. It is recommended that samples be submitted in the original collection device. However, pour-off containers will be accepted. Samples are stable up to 3 days at room temperature and

New Tests and Test Updates

New Tests

should be refrigerated thereafter. DO NOT FREEZE the OraSure Intercept® or Immunalysis QuantisalTM collection devices.

Specimen Container: Oral Fluid collection device
Transport Temperature: Refrigerated
Light Protection: Not Required
Rejection Criteria: None
Stability: Room Temperature: Undetermined
Refrigerated: 21 day(s)
Frozen (-20 °C): Undetermined

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Thursday 2 days (after set-up)
CPT Code: 83788

Compound Name / Alias	Units	RL	Reference Comment
Phencyclidine Angel Dust; PCP; Sherm	ng/mL	4.0	Phencyclidine (PCP) is a DEA Schedule II controlled dangerous hallucinogenic drug. It is subject to abuse and dependence.
Dextromethorphan	ng/mL	100	Dextromethorphan (DXM) is an over the counter antitussive. When taken in excess it causes intoxication and dissociative effects, and is subject to abuse and dependence. This test does not distinguish between dextromethorphan and its isomer levomethorphan.

4790B Vilazodone, Blood **Effective Immediately**

Scope of Analysis: Vilazodone [LC-MS/MS]
Method(s): High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose: Therapeutic Drug Monitoring and Postmortem Forensic Analysis
Category: Antidepressant
Specimen Requirements: 1 mL Blood
Minimum Volume: 0.3 mL
Special Handling: None
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate)
Transport Temperature: Refrigerated
Light Protection: Not Required
Rejection Criteria: None
Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Monday-Sunday 7 days (after set-up)
CPT Code: 83789

Compound Name / Alias	Units	RL	Reference Comment
Vilazodone Viibryd®	ng/mL	5.0	A single 20 mg oral dose resulted in a mean peak plasma concentration of 43 ng/mL (range, 28 - 63 ng/mL) at 5 hours after administration. A single 40 mg oral dose under fed conditions produced a mean peak plasma concentration of 90 ng/mL (range, 60 - 120 ng/mL). After dosing with 40 mg daily under fed conditions, the mean peak steady-state serum concentration was 156 ng/mL. The blood to plasma ratio for this drug is unknown.

New Tests and Test Updates

New Tests

4790SP Vilazodone, Serum/Plasma **Effective Immediately**

Scope of Analysis:	Vilazodone [LC-MS/MS]
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Therapeutic Drug Monitoring and Postmortem Forensic Analysis
Category:	Antidepressant
Specimen Requirements:	1 mL Serum or Plasma
Minimum Volume:	0.3 mL
Special Handling:	Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Specimen Container:	Plastic container (preservative-free)
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	Polymer gel separation tube (SST or PST).
Stability:	Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Monday-Sunday 7 days (after set-up)

CPT Code: 83789

Compound Name / Alias	Units	RL	Reference Comment
Vilazodone Viibryd®	ng/mL	5.0	A single 20 mg oral dose resulted in a mean peak plasma concentration of 43 ng/mL (range, 28 - 63 ng/mL) at 5 hours after administration. A single 40 mg oral dose under fed conditions produced a mean peak plasma concentration of 90 ng/mL (range, 60 - 120 ng/mL). After dosing with 40 mg daily under fed conditions, the mean peak steady-state serum concentration was 156 ng/mL.

New Tests and Test Updates

Test Changes

2526B Leflunomide as Metabolite, Blood

Summary of Changes: Specimen Requirements were changed.

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: NMS Labs has no experimental or literature-based data regarding the choice of specific specimen collection containers for this test.
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None

4030B Pyridine, Blood

Summary of Changes: Units were changed.

Scope of Analysis: GC (82491): Pyridine
Method (CPT Code)

Compound Name	Units	Reference Comment
Pyridine	mcg/mL	No reference data available.

4030SP Pyridine, Serum/Plasma

Summary of Changes: Units were changed.

Scope of Analysis: GC (82491): Pyridine
Method (CPT Code)

Compound Name	Units	Reference Comment
Pyridine	mcg/mL	No reference data available.

4030U Pyridine, Urine

Summary of Changes: Units were changed.

Scope of Analysis: GC (82491): Pyridine
Method (CPT Code)

Compound Name	Units	Reference Comment
Pyridine	mcg/mL	No reference data available.

New Tests and Test Updates

Discontinued Tests

Test Code	Test Name	Alternative Test
0478FL	Astemizole and Metabolite, Fluid	No Alternate Tests Available
0478SP	Astemizole and Metabolite, Serum/Plasma	No Alternate Tests Available
0478TI	Astemizole and Metabolite, Tissue	No Alternate Tests Available
1140SP	Chloroquine, Serum/Plasma	1140P - Chloroquine, Plasma
8602B	Methamphetamine and Metabolite, Blood	2810B - Methamphetamine and Metabolite, Blood
8602FL	Methamphetamine and Metabolite, Fluid	2810FL - Methamphetamine and Metabolite, Fluid
8602SP	Methamphetamine and Metabolite, Serum/Plasma	2810SP - Methamphetamine and Metabolite, Serum/Plasma
8602TI	Methamphetamine and Metabolite, Tissue	2810TI - Methamphetamine and Metabolite, Tissue
8602U	Methamphetamine and Metabolite, Urine	2810U - Methamphetamine and Metabolite, Urine

NMS LABS
3701 Welsh Road
Willow Grove, PA 19090
www.NMSLabs.com